GHRP-2 vs Ipamorelin
Side-by-side comparison of GHRP-2, Ipamorelin — mechanism, dosing, half-life, side effects, and research status.
| Attribute | GHRP-2 Growth Hormone Releasing Peptide-2 Growth Hormone | Ipamorelin Ipamorelin (Selective GHRP) Growth Hormone |
|---|---|---|
| Basics | ||
| Molecular type | Growth Hormone Releasing Peptide (GHRP) | Growth Hormone Releasing Peptide (GHRP) |
| Amino acids | 6 | 5 |
| Molecular weight | 817.9 Da | 711.9 Da |
| Half-life | ~1–2 hours | ~2 hours |
| Route(s) | Subcutaneous, Intramuscular, Intranasal | Subcutaneous, Intramuscular |
| Mechanism & Research | ||
| Primary mechanism | GHRP-2 activates the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus. Hypothalamic activation leads to reduced somatostatin tone (the GH release inhibitor), while pituitary activation directly triggers GH se… | Ipamorelin activates growth hormone secretagogue receptors (GHSR-1a) in the pituitary, triggering pulsatile GH release. Unlike first-generation GHRPs (GHRP-6, GHRP-2), ipamorelin's selectivity for GHSR-1a is high enough … |
| Research status | Research Compound | Research Compound |
| Evidence summary | GHRP-2 has been extensively studied in humans including as a diagnostic tool for GH deficiency assessment. Its well-characterised dose-response relationship makes it a reference compound in the GHRP class. | Ipamorelin was among the first highly selective GHRPs to enter research. Phase 1 trials confirmed its clean hormonal profile. It remains a reference GHRP in comparative studies and is widely used as the GHRP component in… |
| Protocol & Dosing | ||
| Typical dose | 100–200 mcg per injection | 100–300 mcg per injection |
| Frequency | 2–3x daily | 2–3x daily (or 1x at bedtime) |
| Duration | 8–12 weeks | 8–12 weeks on, 4 weeks off |
| Timing | Fasted state; 2+ hours post-meal | Fasted state or 2+ hours post-meal for maximum GH response; bedtime dosing utilises natural nocturnal GH pulse |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Prohibited (WADA S2) | Prohibited (WADA S2) |
| Deeper reading | ||
| Related peptides | Ipamorelin, CJC-1295, GHRP-6, Hexarelin | CJC-1295, GHRP-2, Sermorelin, Tesamorelin |
| Full profile | Read full GHRP-2 profile → | Read full Ipamorelin profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.